Thompson Siegel & Walmsley LLC Has $13.02 Million Stake in AbbVie Inc. (NYSE:ABBV)

Thompson Siegel & Walmsley LLC lessened its position in AbbVie Inc. (NYSE:ABBV) by 0.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,286 shares of the company’s stock after selling 53 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in AbbVie were worth $13,023,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Impact Capital Partners LLC acquired a new position in shares of AbbVie during the fourth quarter worth $3,893,000. CFO4Life Group LLC grew its holdings in AbbVie by 7.1% during the 4th quarter. CFO4Life Group LLC now owns 3,197 shares of the company’s stock worth $568,000 after acquiring an additional 212 shares during the period. Balboa Wealth Partners raised its position in shares of AbbVie by 4.5% during the fourth quarter. Balboa Wealth Partners now owns 7,193 shares of the company’s stock worth $1,278,000 after purchasing an additional 308 shares during the period. Erste Asset Management GmbH lifted its holdings in shares of AbbVie by 7.5% in the fourth quarter. Erste Asset Management GmbH now owns 139,949 shares of the company’s stock valued at $24,911,000 after purchasing an additional 9,765 shares in the last quarter. Finally, Tredje AP fonden boosted its position in shares of AbbVie by 2.2% during the fourth quarter. Tredje AP fonden now owns 749,458 shares of the company’s stock valued at $133,179,000 after buying an additional 16,338 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Leerink Partners raised AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 price target for the company in a research report on Friday, November 22nd. Bank of America increased their target price on shares of AbbVie from $200.00 to $223.00 and gave the company a “neutral” rating in a report on Tuesday, March 4th. Piper Sandler Companies restated an “overweight” rating and set a $220.00 price target on shares of AbbVie in a report on Tuesday, December 17th. Guggenheim increased their price objective on shares of AbbVie from $212.00 to $214.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, Daiwa Capital Markets downgraded AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price on the stock. in a research note on Thursday, December 5th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $211.45.

AbbVie Stock Performance

NYSE:ABBV opened at $211.19 on Friday. The business’s fifty day moving average is $190.48 and its 200 day moving average is $188.06. The firm has a market cap of $372.83 billion, a price-to-earnings ratio of 88.00, a PEG ratio of 1.62 and a beta of 0.61. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $218.66.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period in the prior year, the firm earned $2.79 EPS. Research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.11%. AbbVie’s dividend payout ratio (DPR) is currently 273.33%.

Insider Activity

In other news, SVP Kevin K. Buckbee sold 18,944 shares of the business’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $203.41, for a total transaction of $3,853,399.04. Following the completion of the transaction, the senior vice president now owns 11,496 shares of the company’s stock, valued at approximately $2,338,401.36. The trade was a 62.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy J. Richmond sold 29,917 shares of the firm’s stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the completion of the sale, the executive vice president now directly owns 44,284 shares in the company, valued at $8,985,223.60. This represents a 40.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,439 shares of company stock worth $11,377,057 in the last three months. Corporate insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.